Levofloxacin

Antibiotic

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Anti-Infective

General information

Levofloxacin is an antibiotic sold under many names, e.g. Quinsair®. It was approved for medical use in the USA in 1996. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, tuberculosis, urinary tract infections, chronic prostatitis, and gastroenteritis. In relation to cystic fibrosis, our AIM tool found the data that levofloxacin inhalation solution can be a safe and effective therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

Levofloxacin on PubChem
Levofloxacin on DrugBank
Levofloxacin on Wikipedia

Synonyms

LIS, MP-376, Aeroquin

Marketed as

Dietary sources

N/A

Structure not available

C18H20FN3O4

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
General effect
3 6.55
Link Tested on Impact factor Notes
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. humans 3.85 As effective as tobramycin.
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. humans 4.73
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. humans 11.08

Does not treat

Mutation Number of sources Average impact factor